GlassScriptPhysician profile
Charles Lawrence Head
NPI 1295423283
$1,555.83
in general payments reported to CMS, 2019-2025
12 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,153 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $624.99 | 2024-2025 | Belbuca, Xtampza, Nucynta |
| Janssen Pharmaceuticals, INC | $289.48 | 2024 | Spravato |
| Abbvie INC. | $243.48 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.69 | 2024-2025 | Relistor, Trulance |
| Vertex Pharmaceuticals Incorporated | $40.81 | 2024-2025 | |
| Pfizer INC. | $29.32 | 2024-2025 | |
| Averitas Pharma INC. | $22.12 | 2024 | Qutenza |
| Tersera Therapeutics LLC | $22.06 | 2024 | Prialt |
| Axsome Therapeutics, INC. | $20.25 | 2024 | Sunosi |
| Lundbeck LLC | $18.49 | 2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $16.07 | 2024 | Quviviq |
| Amgen INC. | $14.07 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.